Comprehensive molecular characterization of urothelial bladder carcinoma.

Détails

ID Serval
serval:BIB_0D73895A86B1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Comprehensive molecular characterization of urothelial bladder carcinoma.
Périodique
Nature
Collaborateur(s)
Cancer Genome Atlas Research Network
Contributeur(s)
Weinstein J.N., Akbani R., Broom B.M., Wang W., Verhaak R.G., McConkey D., Lerner S., Morgan M., Creighton C.J., Smith C., Kwiatkowski D.J., Cherniack A.D., Kim J., Sekhar Pedamallu C., Noble M.S., Al-Ahmadie H.A., Reuter V.E., Rosenberg J.E., Bajorin D.F., Bochner B.H., Solit D.B., Koppie T., Robinson B., Gordenin D.A., Fargo D., Klimczak L.J., Roberts S.A., Au J., Laird P.W., Hinoue T., Schultz N., Ramirez R., Hansel D., Hoadley K.A., Kim W.Y., Damrauer J.S., Baylin S.B., Mungall A.J., Robertson A.G., Chu A., Kwiatkowski D.J., Sougnez C., Cibulskis K., Lichtenstein L., Sivachenko A., Stewart C., Lawrence M.S., Getz G., Lander E., Gabriel S.B., Creighton C.J., Donehower L., Cherniack A.D., Kim J., Carter S.L., Saksena G., Schumacher S.E., Sougnez C., Freeman S.S., Jung J., Sekhar Pedamallu C., Bhatt A.S., Pugh T., Getz G., Beroukhim R., Gabriel S.B., Meyerson M., Mungall A.J., Robertson A.G., Chu A., Ally A., Balasundaram M., Butterfield Y.S., Dhalla N., Hirst C., Holt R.A., Jones S.J., Lee D., Li H.I., Marra M.A., Mayo M., Moore R.A., Schein J.E., Sipahimalani P., Tam A., Thiessen N., Wong T., Wye N., Bowlby R., Chuah E., Guin R., Jones S.J., Marra M.A., Hinoue T., Shen H., Bootwalla M.S., Triche T., Lai P.H., Van Den Berg D.J., Weisenberger D.J., Laird P.W., Hansel D., Hoadley K.A., Balu S., Bodenheimer T., Damrauer J.S., Hoyle A.P., Jefferys S.R., Meng S., Mose L.E., Simons J.V., Soloway M.G., Wu J., Kim W.Y., Parker J.S., Hayes D.N., Roach J., Buda E., Jones C.D., Mieczkowski P.A., Tan D., Veluvolu U., Waring S., Auman J.T., Perou C.M., Wilkerson M.D., Santoso N., Parfenov M., Ren X., Pantazi A., Hadjipanayis A., Seidman J., Kucherlapati R., Lee S., Yang L., Park P.J., Baylin S.B., Wei Xu A., Protopopov A., Zhang J., Bristow C., Mahadeshwar H.S., Seth S., Song X., Tang J., Zeng D., Chin L., Guo C., Weinstein J.N., Akbani R., Broom B.M., McConkey D., Casasent T.D., Liu W., Ju Z., Motter T., Peng B., Ryan M., Wang W., Verhaak R.G., Su X., Yang J.Y., Lorenzi P.L., Yao H., Zhang N., Zhang J., Mills G.B., Kim J., Noble M.S., Cho J., DiCara D., Frazer S., Gehlenborg N., Heiman D.I., Lin P., Liu Y., Stojanov P., Voet D., Zhang H., Zou L., Chin L., Getz G., Bernard B., Kreisberg D., Reynolds S., Rovira H., Shmulevich I., Ramirez R., Schultz N., Gao J., Jacobsen A., Aksoy B.A., Antipin Y., Ciriello G., Dresdner G., Gross B., Lee W., Reva B., Shen R., Sinha R., Sumer S.O., Weinhold N., Ladanyi M., Sander C., Benz C., Carlin D., Haussler D., Ng S., Paull E.O., Stuart J., Zhu J., Liu Y., Zhang W., Taylor B.S., Lichtenberg T.M., Zmuda E., Barr T., Black A.D., George M., Hanf B., Helsel C., McAllister C., Ramirez N.C., Tabler T.R., Weaver S., Wise L., Bowen J., Gastier-Foster J.M., Weinstein J.N., Lerner S., Jian W., Tello S., Ittman M., Castro P., McClenden W.D., Morgan M., Gibbs R., Liu Y., Saller C., Tarvin K., DiPiero J.M., Owens J., Bollag R., Li Q., Weinberger P., Czerwinski C., Huelsenbeck-Dill L., Iacocca M., Petrelli N., Rabeno B., Swanson P., Shelton T., Curley E., Gardner J., Mallery D., Penny R., Van Bang N., Thi Hanh P., Kohl B., Van Le X., Duc Phu B., Thorp R., Viet Tien N., Quang Vinh L., Sandusky G., Burks E., Christ K., Gee J., Holway A., Moinzadeh A., Sorcini A., Sullivan T., Al-Ahmadie H.A., Bajorin D.F., Bochner B.H., Garcia-Grossman I.R., Regazzi A.M., Solit D.B., Rosenberg J.E., Reuter V.E., Koppie T., Boice L., Kimryn Rathmell W., Thorne L., Bastacky S., Davies B., Dhir R., Gingrich J., Hrebinko R., Maranchie J., Nelson J., Parwani A., Bshara W., Gaudioso C., Morrison C., Alexopoulou V., Bartlett J., Engel J., Kodeeswaran S., Antic T., O'Donnell P.H., Smith N.D., Steinberg G.D., Egea S., Gomez-Fernandez C., Herbert L., Jorda M., Soloway M., Beaver A., Carter S., Kapur P., Lewis C., Lotan Y., Robinson B., Hansel D., Guo C., Bondaruk J., Czerniak B., Akbani R., Broom B.M., Liu Y., Zhang W., Weinstein J.N., Lerner S., Morgan M., Kim J., Cherniack A.D., Freeman S.S., Sekhar Pedamallu C., Noble M.S., Kwiatkowski D.J., Al-Ahmadie H.A., Bajorin D.F., Bochner B.H., Solit D.B., Rosenberg J.E., Reuter V.E., Koppie T., Robinson B., Skinner E., Ramirez R., Schultz N., Hansel D., Kim W.Y., Guo C., Bondaruk J., Aldape K., Czerniak B., Jensen M.A., Kahn A.B., Pihl T.D., Pot D.A., Srinivasan D., Wan Y., Ferguson M.L., Zenklusen J.C., Davidsen T., Demchok J.A., Mills Shaw K.R., Sheth M., Tarnuzzer R., Wang Z., Yang L., Hutter C., Ozenberger B.A., Sofia H.J., Eley G.
ISSN
1476-4687 (Electronic)
ISSN-L
0028-0836
Statut éditorial
Publié
Date de publication
20/03/2014
Peer-reviewed
Oui
Volume
507
Numéro
7492
Pages
315-322
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural
Publication Status: ppublish
Résumé
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we report here an integrated analysis of 131 urothelial carcinomas to provide a comprehensive landscape of molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved in cell-cycle regulation, chromatin regulation, and kinase signalling pathways, as well as 9 genes not previously reported as significantly mutated in any cancer. RNA sequencing revealed four expression subtypes, two of which (papillary-like and basal/squamous-like) were also evident in microRNA sequencing and protein data. Whole-genome and RNA sequencing identified recurrent in-frame activating FGFR3-TACC3 fusions and expression or integration of several viruses (including HPV16) that are associated with gene inactivation. Our analyses identified potential therapeutic targets in 69% of the tumours, including 42% with targets in the phosphatidylinositol-3-OH kinase/AKT/mTOR pathway and 45% with targets (including ERBB2) in the RTK/MAPK pathway. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities.
Mots-clé
Cell Cycle/genetics, Chromatin/genetics, Chromatin/virology, Down-Regulation/genetics, Gene Expression Regulation, Neoplastic/genetics, Humans, MicroRNAs/genetics, MicroRNAs/metabolism, Molecular Targeted Therapy, Oxidative Stress/genetics, Phosphatidylinositol 3-Kinases/metabolism, Protein Kinases/genetics, Protein Kinases/metabolism, Proto-Oncogene Proteins c-akt/metabolism, RNA, Messenger/genetics, RNA, Messenger/metabolism, Signal Transduction/genetics, TOR Serine-Threonine Kinases/metabolism, Urinary Bladder Neoplasms/drug therapy, Urinary Bladder Neoplasms/genetics, Urinary Bladder Neoplasms/pathology, Urinary Bladder Neoplasms/virology, Virus Integration/genetics
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/11/2018 9:30
Dernière modification de la notice
20/08/2019 12:34
Données d'usage